SavedAdd your journal

Journals / Uluslararası Hematoloji-Onkoloji Dergisi / 2018 / Cilt: 28 - Sayı: 2

Lung Cancer Related Central Airway Obstruction: Who Benefits Better from Radiotherapy?

Akciğer Kanseri İlişkili Santral Hava Yolu Tıkanıklığı: Radyoterapiden Kim Daha Fazla Fayda Görür?

Erkan TOPKAN
Yurday OZDEMIR
Berna A. YILDIRIM
Pages
86–94
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The primary end-point was radiologic response, while overall- (OS) and CAO-free survival, and predictors of better outcomes constituted secondary endpoints.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:We aimed to assess the efficacy of external beam radiotherapy (EBRT) in central airway obstruction (CAO) and associated factors for metastatic lung cancer (MLC) patients.
📊
Key Findings & Data:Records of 72 MLC patients presenting with CAO were retrospectively analyzed.
💡
Conclusion & Impact:The primary end-point was radiologic response, while overall- (OS) and CAO-free survival, and predictors of better outcomes constituted secondary endpoints.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

We aimed to assess the efficacy of external beam radiotherapy (EBRT) in central airway obstruction (CAO) and associated factors for metastatic lung cancer (MLC) patients. Records of 72 MLC patients presenting with CAO were retrospectively analyzed. The serial chests X-rays prior and after the EBRT were compared for response assessment. The primary end-point was radiologic response, while overall- (OS) and CAO-free survival, and predictors of better outcomes constituted secondary endpoints. The EBRT doses ranged between 8 to 40 Gy (1-13 fractions). Median follow-up and OS were 5.6 (range: 1.3-17.8) and 7.6 months (95% CI: 6.5-8.7), respectively. Objective CAO resolution was achieved in 58 patients (80.6%) on serial chest X-rays with a median time to maximum CAO response of 23 days (range: 3-86). In responders the response was durable (8.1 months) almost nearly for all their remaining life spans (8.3 months) with only 19.0% CAO recurrences. Median OS was also significantly longer in responders (8.3 vs. 2.4 months; p< 0.001). Small-cell histology (p= 0.002), tumor size

Özet

Metastatik akciğer kanserine (MAK) bağlı gelişen santral hava yolu tıkanıklığının (SHT) palyatif tedavisinde radyoterapinin (RT) etkinliği ve etkinlikle ilişkili faktörlerin araştırılması amaçlanmıştır. Bu amaçla 72 hasta geriye dönük olarak incelenmiştir. RT’ye cevap değerlendirmesi seri akciğer grafileri (SAG) kullanılarak yapılmıştır. Primer sonlanım noktası radyolojik cevap; ikincil sonlanım noktaları genel sağ kalım (GS), SHT’siz sağ kalım ve daha iyi sonuç göstergelerinin araştırılması olarak belirlenmiştir. RT dozları 8-40 Gy’dir (1-13 fraksiyon). Ortanca takip süresi ve GS sırasıyla 5.6 (aralık: 1.3-17.8) ve 7.6 (95% CI: 6.5-8.7) aydır. SAG ile takipte 58 (%80.6) hastada objektif yanıt elde edilmiş olup SHT’deki maksimum düzelme ortanca 23 günde (3-86) gerçekleşmiştir. RT’ye yanıt veren hastalardaki ortanca 8.3 aylık GS süresinin 8.1 ayında amaçlanan palyasyon sağlanırken; hastaların %19’da SHT tekrarlamıştır. Ortanca GS süresi RT’ye yanıt veren (8.3 karşın 2,4 ay; p< 0.001) hastalarda daha yüksek bulunmuştur. Küçük hücreli histoloji (p= 0.002), tümör boyutu-nun

🔖

Cite This Article

TOPKAN, E., OZDEMIR, Y., YILDIRIM, B. A. (2022). Lung Cancer Related Central Airway Obstruction: Who Benefits Better from Radiotherapy?. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 28 - Sayı: 2, 86–94. https://ajindex.com/articles/644784

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Willner J, Baier K, Caragiani E, et al. Dose, volume, and tu-mor control prediction in primary radiotherapy of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 52: 382-389,2002.
  2. Harms W, Schraube P, Becker H, et al. Effect and toxicity of endoluminal high-dose-rate (HDR) brachytherapy in centrally located tumors of the upper respiratory tract. Strahlenther Onkol 176: 60-66, 2000.
  3. Tanaka H, Hayashi S, Ohtakara K, Hoshi H. Palliative radio-therapy for patients with tracheobronchial and esophageal compression due to intrathoracic malignant tumors. Asia Pac J Clin Oncol 8(4): e82-8, 2012. Turrisi AT 3rd, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340: 265-271, 1999.
  4. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combi-nation with mitomycin, vindesine, and cisplatin in unresect-able stage III non-small-cell lung cancer. J Clin Oncol 17: 2692-2699, 1999.
  5. Curran WJ, Jr., Paulus R, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: ran-domized phase III trial RTOG 9410. J Natl Cancer Inst 103: 1452-1460, 2011. McGarry RC. Extensive-Stage Small Cell Lung Cancer: Is Consolidative Thoracic Radiation Therapy Really a New Standard of Care? Int J Radiat Oncol Biol Phys 93: 10-12 2015.
  6. Carney DN, Mitchell JB, Kinsella TJ. In vitro radiation and chemotherapy sensitivity of established cell lines of human small cell lung cancer and its large cell morphological vari-ants. Cancer Res 43: 2806-2811, 1983.
  7. Stinchcombe TE, Gore EM. Limited-stage small cell lung cancer: current chemoradiotherapy treatment paradigms. Oncologist 15: 187-195, 2010.
  8. Fairchild A, Harris K, Barnes E, et al. Palliative thoracic radio-therapy for lung cancer: a systematic review. J Clin Oncol 26: 4001-411, 2008.
  9. Lee JW, Lee JH, Kim HK, et al. The efficacy of external beam radiotherapy for airway obstruction in lung cancer patients. Cancer Res Treat 47: 189-196, 2015.
  10. Speiser BL, Spratling L. Remote afterloading brachytherapy for the local control of endobronchial carcinoma. Int J Radiat Oncol Biol Phys 25: 579-587, 1993.
  11. Stout R, Barber P, Burt P, et al. Clinical and quality of life outcomes in the first United Kingdom randomized trial of endobronchial brachytherapy (intraluminal radiotherapy) vs. external beam radiotherapy in the palliative treatment of inop